In re Appln. of Kovesdi et al. Application No. Not Assigned (Continuation of U.S. Patent App. No. 08/258,416)

reading frame of the existing mini-ORF or by introducing yet another expression cassette containing its own promoter sequences, polyadenylation signals, and stop sequences in addition to the gene of interest.

Page 30, lines 27-29, please amend the paragraph to read as follows.

This cell line is suitable for complementing vectors that are deficient in the E1 and E4 regions, such as the $Ad_{GV}CFTR.12$ series of vectors.

Page 30, line 35, through page 31, line 18, please amend the paragraph to read as follows:

The E2A expression cassette for introduction into 293/E4 cells is

produced as follows. The first step is to alter surrounding bases of the ATG of E2A to make a perfect Kozak consensus (Kozak, J. Molec. Biol., 196, 947-950 (1987)) to optimize expression of E2A. Two primers are designed to alter the 5' region of the E2A gene. Ad5s(23884), an 18 bp oligonucleotide (5'GCCGCCTCATCCGCTTTT3') (SEQ ID NO:3), is designed to prime the internal region flanking the Sma I site of the E2A gene. DBP(ATG)R1, a 32 bp oligonucleotide (5'CCGGAATTCCACCATGGCGAGTCGGGAAGAGG3') (SEQ ID NO:4), is designed to introduce the translational consensus sequence around the ATG of the E2A gene modifying it into a perfect Kozak extended consensus sequence and to introduce an Eco RI site just 5' to facilitate cloning. The resulting PCR product using the above primers is digested with Eco RI and Sma I (NEB) and cloned into the identical polylinker sites of pBluescript IIKS+ (Stratagene, La Jolla, CA). The resulting plasmid is named pKS/ESDBP.

IN THE CLAIMS:

Please cancel claims 1-35.

In re Appln. of Kovesdi et al. Application No. Not Assigned (Continuation of U.S. Patent App. No. 08/258,416)

Please add the following new claims:

- 36. (New) A recombinant cell line for the production of a defective adenovirus, comprising, inserted into its genome, part of an adenovirus E4 region comprising an ORF6 reading frame under the control of a functional promoter, wherein the inserted E4 region does not contain a functional ORF4 reading frame.
- 37. (New) The cell line according to claim 36, wherein the E4 region is derived from a group C human adenovirus genome.
- 38. (New) The cell line according to claim 37, wherein the E4 region is derived from the genome of an Ad2 or Ad5 adenovirus.
- 39. (New) The cell line according to claim 36, wherein the promoter is an inducible promoter.
- 40. (New) The cell line according to claim 36, which transcomplements for the E1 region.
 - 41. (New) The cell line according to claim 40, which is derived from cell line 293.
- 42. (New) The cell line according to claim 36, wherein the part of the E4 region does not contain ORF4.
- 43. (New) The cell line according to claim 42, wherein the part of the E4 region does not contain ORF1-ORF4.
- carrying a reading frame ORF6 under the control of an inducible promoter.